These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11177158)

  • 1. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study.
    Ng EY; Yeung WS; Ho PC
    Hong Kong Med J; 2000 Dec; 6(4):368-74. PubMed ID: 11177158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome.
    Yovich JL; Alsbjerg B; Conceicao JL; Hinchliffe PM; Keane KN
    Drug Des Devel Ther; 2016; 10():2561-73. PubMed ID: 27563236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.
    Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ
    BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
    Out HJ; Lindenberg S; Mikkelsen AL; Eldar-Geva T; Healy DL; Leader A; Rodriguez-Escudero FJ; Garcia-Velasco JA; Pellicer A
    Hum Reprod; 1999 Mar; 14(3):622-7. PubMed ID: 10221686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization.
    Latin-American Puregon IVF Study Group
    Fertil Steril; 2001 Nov; 76(5):950-6. PubMed ID: 11704116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count.
    Jayaprakasan K; Hopkisson J; Campbell B; Johnson I; Thornton J; Raine-Fenning N
    BJOG; 2010 Jun; 117(7):853-62. PubMed ID: 20353458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.
    Hoomans EH; Mulder BB;
    J Assist Reprod Genet; 2002 Oct; 19(10):470-6. PubMed ID: 12416651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.
    Trew GH; Brown AP; Gillard S; Blackmore S; Clewlow C; O'Donohoe P; Wasiak R
    Reprod Biol Endocrinol; 2010 Nov; 8():137. PubMed ID: 21059191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.
    Out HJ; Braat DD; Lintsen BM; Gurgan T; Bukulmez O; Gökmen O; Keles G; Caballero P; González JM; Fábregues F; Balasch J; Roulier R
    Hum Reprod; 2000 Jan; 15(1):29-35. PubMed ID: 10611184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.